NCT02764086 is a Phase 1, PHASE2 clinical trial of Radiation in Non-Small Cell Lung Cancer, sponsored by Cancer Trials Ireland.

Who is sponsoring NCT02764086?

NCT02764086 is sponsored by Cancer Trials Ireland.

What drugs are being tested in NCT02764086?

Interventions in NCT02764086: Radiation.

What condition does NCT02764086 study?

NCT02764086 studies Non-Small Cell Lung Cancer.

Is NCT02764086 still recruiting?

NCT02764086 is currently terminated. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT02764086

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer

Terminated Phase 1, PHASE2 Last updated 13 April 2026

What this trial tests

Phase 1, PHASE2 trial testing Radiation in Non-Small Cell Lung Cancer in 6 participants. Terminated before completion.

Timeline

10 August 2016

Primary endpoint
5 June 2020

5 June 2020

Quick facts

Lead sponsor	Cancer Trials Ireland
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	10 August 2016
Primary completion	5 June 2020
Estimated completion	5 June 2020
Sites	1 location across Ireland

Drugs / interventions tested

Radiation

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Cancer Trials Ireland — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective non-randomised Phase I/II study with patients recruited to escalated dose cohorts. Escalated dose to the iGTV (internal gross tumour volume), with 60 Gy to the conventional PTV (planning target volume), will be delivered to successive cohorts of participants (6-12 participants/cohort) until the maximum tolerated oesophageal dose is determined. The minimum dose will be 60 Gy delivered via intensity modulated radiation therapy (IMRT) or volume modulated arc therapy (VMAT), planned on an Average Intensity Projection (AVIP) dataset. Standard of care chemotherapy. There will be two treatment arms; one with patients who are planned to receive neo-adjuvant or no chemotherapy, and the other with patients who are planned to receive concurrent chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy.
Yegya-Raman N, Zou W, Nie K, Malhotra J, et al · · 2018 · cited 24× · PMID 30206493 · DOI 10.21037/jtd.2018.07.29

Verify or expand the search:

Other trials of Radiation

Trials testing the same drug.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07141147 — A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Lo · NA · not yet recruiting
NCT06270888 — Hypofractionation (Radiation) Trial for Multiple Myeloma · Phase 1 · recruiting
NCT06875583 — The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial · NA · recruiting
NCT07046221 — Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery · Phase 2 · not yet recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Cancer Trials Ireland trials

Trials by the same sponsor.

NCT07425002 — Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM) · NA · recruiting
NCT06078813 — Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases · Phase 1, PHASE2 · recruiting
NCT05710666 — Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast · Phase 2 · active not recruiting
NCT05518110 — PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Canc · Phase 2 · terminated
NCT05123131 — Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02764086 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Trials Ireland
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02764086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing